Lonza Licenses Gene Expression Technology to Sorrento - - BioPharm International

ADVERTISEMENT

Lonza Licenses Gene Expression Technology to Sorrento



The biopharmaceutical company Sorrento Therapeutics and Lonza have formed a nonexclusive research license agreement, under which Sorrento gains access to Lonza’s GS Xceed Gene Expression System. The GS Xceed System is used in the generation of stable expression cell lines for the production and development of therapeutic antibodies in Sorrento’s product portfolio.

The research license agreement will give Sorrento access to Lonza’s GS technology for use in Sorrento’s maturing pipeline of therapeutic antibodies in oncology, inflammation, and infectious disease. Sorrento has shown yields of up to 3g/L with the GS Xceed System, in the production of antibodies targeting the vascular epidermal growth factor receptor 2 (VEGFR2), an important anti-angiogenesis target for a number of solid tumor indications. Several monoclonal antibodies (mAbs) will be produced and developed under the new agreement, including Sorrento’s lead anti-PD-L1 and anti-PD-1 antibodies, as well as a selection of traditionally difficult-to-obtain anti-chemokine receptor mAbs.

Source: Lonza
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Author Guidelines

Click here